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Introduction
Recent Prostate Imaging Reporting and Data System 
version 2 (PI-RADS v2) using multiparametric magnetic 
resonance imaging (mpMRI) [T2-weighted imaging 
(T2WI), diffusion-weighted imaging (DWI) and dynamic 
contrast-enhanced magnetic resonance imaging (DCE-
MRI)], established the guidelines to promote global 
standardization of prostate imaging, to improve detection, 
localization, characterization and risk stratification of 
prostate cancer (PCa) as well as to improve communication 
with referring urologists (1). 
PI-RADS v2 determines the role of each sequence 
(T2WI, DWI and DCE) and, by combining and assessing 
on a 5 point category scale the findings on each sequence, 
correlates with the presence of clinically significant PCa and 
its localization. 
Among potential ambiguities and gaps (2), an unclear 
guidance on clinical management for each one of the five 
categories has emerged. Particularly, the PI-RADS score 
3 is insufficient for decision-making (biopsy or not biopsy) 
and the positive DCE upgrading this category to a score 4 
is irrelevant (3,4). 
In this scenario, some Authors have recently proposed 
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a standardization and simplification of PI-RADS v2 using 
the bpMRI approach (5-7). Diagnosis of PCa is histological. 
BpMRI typically meets the objective of detection and 
localization of PCa suspected foci as well as the execution 
of MRI-targeted or MRI-TRUS-guided fusion prostate 
biopsy. Depiction of index lesion and its volume by bpMRI 
could represent a potential alternative tool to determine 
PCa presence and severity, to guide patient’s management 
and to defeat the use of contrast material in patients 
suspected of PCa.
We here reviewed the role of DCE-MRI. The potential 
contributes of bpMRI (T2WI and DWI) and lesion volume 
in the diagnosis and management of suspected PCa were 
reported as well. 
Current state of MRI sequences in the diagnosis 
of PCa
Despite the detailed information provided by the American 
College of Radiology (ACR) (8), the working group of the 
European Society of Urogenital Radiology (ESUR) (9) and 
the latest version of PI-RADS 2.0 (1), the “gold standard” 
for evaluating PCa aggressiveness is the Gleason score (GS), 
measured after prostate biopsy or radical prostatectomy.
Since the correlation between mpMRI and PCa 
aggressiveness remains controversial (1), the main objective 
of mpMRI is the detection and localization of suspicious 
PCa.
In the PI-RADS v2 spectroscopy has been omitted 
and DCE has assumed a minor role; DWI and T2WI are 
respectively considered the predominant sequences for 
lesion detection in peripheral zone (PZ) and transitional 
zone (TZ) (1). T2WI and DWI seem to be sufficient for co-
registration of MRI-TRUS images and then for guidance 
of subsequent biopsy of suspicious lesions identified by 
bpMRI. 
DCE-MRI potential and drawbacks 
According to PI-RADS v2, a lesion in PZ assigned to PI-
RADS 3 score is upgraded to PI-RADS 4 when it shows 
enhancement by DCE (1). Since the addition of DCE does 
not actually seem to alter the clinical implications (7), the 
role of T2WI and DWI has been emphasized. DCE may 
potentially be useful: 
(I) to help the detection of some subtle tumors which, 
due to small size, poor visual contrast, compared 
to adjacent benign tissue, or a challenging location 
within prostate, tend to be missed using the 
combination of T2WI and DWI alone; 
(II) to aid imaging when imaging quality of T2WI and 
DWI is impaired; 
(III) to assist the scoring level of suspicion for clinical 
significant cancer in case of equivocal lesions; 
(IV) to assess recurrent disease in patients who received 
treatment (2). DCE-MRI can monitor the response 
to treatment and increase the diagnostic accuracy of 
locoregional recurrence in patients who underwent 
radical prostatectomy (sensitivity 46–90%; specificity 
74–96%) (10). Moreover, it has been suggested as 
a promising biomarker for assessing and predicting 
therapeutic response in PCa providing information 
about the action of therapeutics and potentially 
helping to distinguish responders from non-
responders (11); 
(V) to  assess  tumor microvascular izat ion and 
angiogenesis (11). On DCE-MRI, PCa shows 
earlier and stronger enhancement of vessels than 
surrounding normal prostate tissue does (12). 
Contrary to the above mentioned potential values, DCE 
in PCa exhibits the following defective features: 
(I) DCE is a not-specific sequence to detect PCa in 
the peripheral, transitional and central zone and 
to determine tumor aggressiveness correlated 
with the type of enhancement curve. Moreover, 
it is often difficult to differentiate small areas of 
enhancement, especially in the transitional area, 
from the adjacent normal prostate tissue (10);
(II) DCE sequences and curve type play a secondary 
role in the accurate determination of lesion 
category using PI-RADS providing the assessment 
of a positive or negative score (1);
(III) the enhancement curves are not-specific and have 
low sensitivity in identifying suspicious PCa foci. 
Therefore, the role of the DCE should ensure 
the enhancement of suspicious lesions identified 
on T2WI or DWI, compared to the surrounding 
glandular tissue (10);
(IV) DCE score depends on variability in reader 
interpretations, mainly due to ambiguity in the 
definition of positive and negative enhancement (2);
(V) it is moreover not clear how to consider a multifocal 
early background enhancement, while diffuse 
enhancement is considered a negative finding. As a 
consequence, a future improvement of PI-RADS v2 
should be necessary to overcome weaknesses about 
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technical aspects of the acquisition, postprocessing 
and interpretation of DCE (2);
(VI) the optimum imaging period after gadolinium 
injection remains unknown, with subsequent lack 
of standardization in data acquisition protocols. 
DCE additionally displays limits concerning both 
cost and time necessary to complete the study which are 
related to the use of gadolinium-based contrast agents. The 
potential risks of these contrast materials in patients with a 
glomerular filtration <30 mL/min and their accumulation in 
the brain have to be considered (13,14).
Biparametric MRI (bpMRI) protocol and clinical 
results 
At our institution, MRI of the prostate is performed on a 3 T 
scanner (Achieva, Philips Medical Systems, Healthcare, 
Eindhoven, the Netherlands) without an endorectal coil. 
The bpMRI protocol consists of axial T1W gradient-
echo sequence with fat-suppression technique (THRIVE) 
imaging, axial, sagittal and coronal T2W FSE imaging, 
axial DWI sequence with B values of 0, 750, 1,500 and 
2,000 s/mm2 and apparent diffusion coefficient (ADC) maps 
calculation.
On bpMRI data we calculated volumes of both prostate 
and index lesion using the ellipsoidal formula (maximum 
anterior posterior diameter × maximum transverse diameter 
× maximum longitudinal diameter × 0.52) and/or by a 
software with 3D reconstruction. A freehand region of 
interest (ROI) around the seminal vesicles, TZ and PZ of 
the prostate and urethra, from base to the apex is drawn 
and then around the index lesion; the software reproduced, 
automatically and in real-time, 3D volumetric graphic their 
representation in different transparent colors after applied 
translation and rotation. In the meanwhile, the volume 
values, expressed in cm3, were automatically calculated and 
registered.
The knowledge of the value of the individual sequences 
is essential in the detection, localization and management of 
suspicious PCa. 
Several studies demonstrate that DCE has a limited 
contribution to the information provided by T2WI and 
DWI alone or in addition to T2WI and DWI (15-22) and 
with reported sensitivities and specificities of 71–84% and 
33–79%, respectively, for PCa of any grade, and 80–90% 
and 47–86% for high-grade PCa (2,15,17,18,23-32).
The diagnostic value of bpMRI in men with or without 
prior biopsy and combined with prostate-specific antigen 
(PSA) has been validated, resulting an improved accuracy 
for detecting clinically significant PCa and to direct biopsy 
needles under TRUS guidance, after MRI-ultrasonography 
fusion (6,15,33-36). Recently, De Visschere et al. (7) 
demonstrated that the role of DCE is limited for diagnosis 
of clinically significant PCa in patients with elevated PSA 
before biopsy and that DCE should be reserved only to 
those patients with a score 3 lesion on DWI in PZ and 
no suspicious lesion in TZ. The authors demonstrated 
that DCE was redundant in 80.8% of patients while in 
the 19.2% of patients, the supplementary information 
(enhancement or not) was incorrect in approximately 30% 
resulting contrast medium not necessary in the vast majority 
of patients when using PI-RADS v2; in the remaining 
19.2% of patients, the additional information (enhancement 
or not) was incorrect in approximately 30% of the cases, 
resulting in an unnecessary use of DCE in the majority of 
patients evaluated by PI-RADS v2.
In accordance with previous reports, in our experience 
we found that bpMRI and mpMRI have similar diagnostic 
accuracy in the detection of PCa index lesions (Figure 1). 
For our study we examined pat ients  with PSA 
abnormalities, with or without previous negative biopsies, 
submitted to radical prostatectomy. The histological 
findings were considered as standard reference (37).
For the index lesion detection, we measured the 
diagnostic performance of T2WI, DWI and DCE MRI 
alone or combined in bpMRI (T2WI and DWI) or mpMRI 
(T2WI, DWI and DCE). Compared to the standard 
reference, the sensitivity of DWI, T2WI and DCE, alone, 
was in the order: DWI > T2WI > DCE. For DWI, it 
was 97.6%, 100% and 94.7% in the whole prostate or 
for PZ and TZ, respectively. The sensitivity of T2WI 
and of DCE-MRI was low, assuming values of 68.3%, 
47.4% and 86.4% or of 39.02%, 31.6% and 45.4% for 
the whole prostate, TZ and PZ, respectively. Both types 
of combined MRI (bpMRI and mpMRI) exhibited same 
level of sensitivity which corresponded to DWI value 
(100% in PZ, 97.6% and 94.7% in the entire prostate or 
TZ, respectively). Analogous trends were observed by 
assessing the agreement (measured by Cohen’s k coefficient) 
between the MRI approaches and the reference standard. 
As for sensitivity, the agreement of bpMRI and mpMRI 
(which corresponded to the value of DWI alone) were 
identical, indicating that DCE sequence in mpMRI did 
not contribute to index lesion detection in PZ and in 
TZ (37). Evaluating both index and non-index lesions by 
bpMRI, we found 27.6% false-positives and 3.3% false-
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negatives. However, the diagnostic performance of bpMRI 
increased with the size of lesion and, interestingly, assumed 
high values for lesions ≥10 mm, which can only mean a 
reduced risk of both false-positives and false-negative, for 
bpMRI, in the group of the clinically significant lesions 
(GS ≥7) (37).
bpMRI and lesion volume as alternative to  
multiparametric MRI
Although DCE-MRI quantitative parameters have the 
potential to assess PCa aggressiveness (low grade from 
intermediate and high grade) in PZ (38), to date no 
definitive studies have been reported about the correlation 
between DCE and cancer aggressiveness. MRI has the 
greatest potential to depict volumes in clinical relevant 
lesions (2,39-49), and several studies have reported a 
sufficiently reliable correspondence between volume of the 
suspicious lesion (measured on T2WI and DWI) and tumor 
volume measured at histological examination of the prostate 
(50-52).
In this perspective, the bpMRI could be considered a 
reliable tool for estimating volume of PCa as in the case of 
other solid tumors.
PCa is considered a clinically significant neoplasia if 
Gleason score is ≥7 and tumor volume >0.5 mL (53). 
According to the findings mentioned above, the volume 
of the suspicious lesion may have a discriminating role 
in the management of the patients with MRI evidence 
of suspicious lesion at risk for PCa. Since the most 
effective way to reduce overtreatment of PCa is to limit 
its detection in men with low-risk disease, assessment 
of the aggressiveness of the PCa is crucial in identifying 
appropriate patient-tailored management. 
A B
C D
Figure 1 A 72-year-old patient with PSA of 7.3 ng/mL but without previous prostate biopsy. Focal lesion of 10 mm (arrow) in the base 
in the right side of the TZ with moderately low signal intensity on T2WI (A), high signal intensity on high b-value image of the DWI 
(B), low signal on ADC map (C) and moderately contrast enhancement on DCE (D). The lesion was assigned a PI-RADS v2 score of 3. 
The enhancement on DCE was considered irrelevant and biopsy was required because of the suspicious lesion. Targeted biopsy revealed a 
Gleason 3+3 prostate cancer. PSA, prostate-specific antigen; TZ, transitional zone; T2WI, T2-weighted imaging; DWI, diffusion-weighted 
imaging; ADC, apparent diffusion coefficient; DCE, dynamic contrast-enhanced, PI-RADS, prostate imaging reporting and data system.
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In clinical practice, when we take into the account an 
appropriate decision-making (biopsy or active surveillance), 
the main weakness emerging from the PI-RADS v2 is the 
lesion diameter. According to PI-RADS v2, a lesion with a 
PI-RADS score of 4 is upgraded to the higher score when 
its diameter is >15 mm (1). To our knowledge, no studies 
demonstrated a relationship between the lesion diameter 
and cancer aggressiveness. Additionally, in our recent 
experience we found that lesion diameter detected by MRI 
seems not to be able to predict tumor aggressiveness. In 
contrast with histology, indeed, no statistical differences of 
tumor lesion diameter between GS =6 and GS ≥7 groups (37) 
were seen (Figure 2).
PCa often is a solid tumor with a defined three 
dimensional shape. Our recent data demonstrated the 
potential diagnostic power of MRI lesion volume for PCa 
and tumor aggressiveness (differentiation of clinically 
significant cancer >0.5 versus <0.5 mL) (52). Detection 
of aggressive PCa (GS ≥7) increased with the increase of 
lesion volume by 13.8% to 40% or to 55% considering a 
lesion volume <0.5 mL or between 0.5 and 1 mL or >1 mL, 
respectively (P=0.008). In addition, the area under the ROC 
curve (performed by comparing values of tumor lesion 
volume in GS ≥7 and GS =6 groups) was 0.752 (P<0.0001) 
and the cut-off lesion volume was >0.5 mL with a sensitivity 
and specificity of 80% and 60% respectively (52) (Figure 3).
Moreover, although the gold standard for assessment of 
PCa clinical significance are the Gleason score and tumor 
volume, obtained from prostate biopsy and/or radical 
prostatectomy specimens, several studies demonstrated that 
MRI has the greatest potential to depict volumes in clinical 
relevant lesions (50-52).  
Hovewer, the lesion volume has some limits: (I) volume 
calculation of suspected lesion requires the use of an 
appropriate software (because estimation with the ellipsoid 
model might be too rough); (II) although there are several 
studies that show a correlation between volume of neoplasia 
(measured at the final histological examination) and 
volume of suspected lesion (measured with the appropriate 
software), this evidence is not definitive (multicenter, 
prospective studies, etc.).
A new risk stratification system as alternative 
to PI-RADS v2: clinical management and lesion 
categories correlation
PI-RADS v2 score does not offer a clear guidance on the 
clinical management for each one of the five categories. In 
particular, a consensus was reached regarding the need of 
not performing the biopsy for score 1 and 2 lesion and to 
perform biopsy for score 4 and 5 lesion. Conversely, there is 
still no consensus for the management of PI-RADS 3 lesions 
(equivocal for the presence of clinical significant cancer 
and/or indeterminate for biopsy). DCE plays a limited role 
Figure 2 Variability of index tumor and index lesion diameter 
measured by histology and MRI respectively for GS =6 and GS 
≥7 groups. In horizontal graph lines, boxes and whiskers represent 
the median, interquartile range, and range values respectively. 
Comparison between GS =6 and GS >7 was performed using the 
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Figure 3 The area under the ROC curve (performed by comparing 
values of tumor lesion volume in GS ≥7 and GS =6 groups) 
was 0.752 (P<0.0001) and lesion volume showed a sensitivity 
and specificity of 80% and 67% respectively in significant PCa 
prediction.
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and is ignored in TZ and in PZ, except when DWI has been 
assigned a score, then the overall assessment category may 
be upgraded to a score 4 of a positive DCE that in many 
cases may be result redundant. As a consequence, recently 
an alternative overall assessment score by T2WI and DWI 
yielded similar performance as PI-RADS v2 (7).
According to the criteria and lexicon of the PI-RADS 
v2 guidelines (1), in our experience, the image analysis was 
based on the recognition of lesion pattern on DWI (lesion 
hyperintense) and ADC map (lesion moderately/markedly 
hypointense), at first, and on T2WI (lesion moderately 
hypointense/hypointense) sequences, later. DWI, with 
high b values, together with ADC images represented the 
predominant sequence to detect the lesion both in PZ and TZ.
Although the most important limitation for the adoption 
of bpMRI in clinical practice is the lack of a standardized 
Figure 4 A 67-year-old patient with PSA of 4.1 ng/mL but without previous prostate biopsy. Focal lesion of 12 mm (arrow) in the anterior 
TZ of the base of the prostate in the right side with moderately low signal intensity on T2WI (A), high signal intensity on high B value image 
of the DWI (B), low signal on ADC map (C) and moderately contrast enhancement on DCE (D). 3D reconstructions (E,F) showed a lesion 
volume <0.5 mL. The lesion was assigned a PI-RADS v2 score of 3. The enhancement on DCE was considered irrelevant and biopsy was 
required because of the suspicious lesion. Targeted biopsy revealed fibrous hyperplasia. PSA, prostate-specific antigen; TZ, transitional zone; 
T2WI, T2-weighted imaging; DWI, diffusion-weighted imaging; ADC, apparent diffusion coefficient; DCE, dynamic contrast-enhanced; 
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scoring system for risk assessment of suspicious lesions, in 
our experience, the bpMRI and lesion volume calculation 
represent potential tools to manage suspected PCa (biopsy 
in >0.5 mL volume and <0.5 mL volume or no biopsy), in 
particular in PI-RADS 3 lesions. 
Representative cases of bpMRI and lesion volume in 
patients with suspicious PCa are reported in Figures 4-6.
According to others (7), omitting DCE in all patients 
seems reasonable in the clinical situation where prostate 
MRI is used as a method of risk stratification of clinical 
significant PCa in patients with elevated PSA. In addition, 
bpMRI reveals to be a valid tool in the detection of local 
recurrence after prostatectomy.
In our experience bpMRI (DWI sequences and ADC 
maps in association with T2WI), without endorectal coil, as 
an alternative approach to mpMRI examination, is justified 
Figure 5 A 59-year-old patient with PSA of 7.6 ng/mL but without previous prostate biopsy. Focal lesion of 12 mm (arrow) in the anterior 
and posterior TZ in the base of the prostate on the right side with moderately low signal intensity on T2WI (A), high signal intensity on 
high B value image of the DWI (B), low signal on ADC map (C) and moderately contrast enhancement on DCE (D). 3D reconstructions (E,F) 
showed a lesion volume >0.5 mL. The lesion was assigned a PI-RADS v2 score of 4. The enhancement on DCE was considered irrelevant 
and on the basis of lesion volume biopsy was required. Targeted biopsy revealed a Gleason 3+3 prostate cancer. PSA, prostate-specific 
antigen; TZ, transitional zone; T2WI, T2-weighted imaging; DWI, diffusion-weighted imaging; ADC, apparent diffusion coefficient; DCE, 
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(I) to identify and localize lesions in the PZ, TZ and in the 
anterior fibromuscular stroma; (II) by no use of gadolinium-
based contrast agent; (III) by reduction of examination time 
and costs.
A comparative study between mpMRI and bpMRI 
and volume of the lesion measurement is underway. Our 
preliminary data show a higher predictive value of lesion 
volume compared to DCE in terms of overall cancer detection 
rate and cancer aggressiveness. In this perspective, the bpMRI 
and lesion volume index calculation, result more appropriate 
than mpMRI for cancer diagnosis and clinical decision making 
(biopsy or not biopsy) in patients suspected of having PCa.
Conclusions




Figure 6 A 60-year-old patient with PSA of 6.8 ng/mL but without previous prostate biopsy. Focal lesion of 15 mm (arrow) in the anterior 
fibromuscular stroma of the mid-prostate on the left side with moderately low signal intensity on T2WI (A), high signal intensity on high 
B value image of the DWI (B), low signal on ADC map (C) and moderately contrast enhancement on DCE (D). 3D reconstructions (E,F) 
showed a lesion volume >0.5 mL. The lesion was assigned a PI-RADS v2 score of 4. The enhancement on DCE was considered irrelevant 
and on the basis of lesion volume biopsy was required. Targeted biopsy revealed a Gleason 3+4 prostate cancer. PSA, prostate-specific 
antigen; TZ, transitional zone; T2WI, T2-weighted imaging; DWI, diffusion-weighted imaging; ADC, apparent diffusion coefficient; DCE, 
dynamic contrast-enhanced; PI-RADS v2, prostate imaging reporting and data system version 2.
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examination protocols and 3D software improved diagnosis 
of usual and unusual malignancies (54-56). Particularly, 
mpMRI modified the approach to the patient with 
suspicious of PCa and became an useful tool to detect 
clinical significant cancer. However, gadolinium, long test 
times and higher costs represent limits for mpMRI. By 
demonstrating similar diagnostic accuracy of bpMRI and 
mpMRI in the detection of PCa, gadolinium-based contrast 
agent seems not to be strictly necessary in the detection 
and localization of PCa, and bpMRI and lesion volume 
calculation are sufficient for these purposes. We emphasize 
the clinical use of the bpMRI considering the use of no 
gadolinium, reduction of the costs and time required to 
complete the study.
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